Factors associated with disease-free survival after bone marrow transplantation for myelodysplasia in multivariate analysis
| Variables . | Relative risk of relapse or death (95% CI) . | P . |
|---|---|---|
| Age, y5-150 | ||
| (1) Younger than 18 | 1.00 | P5-152overall = .0002 |
| (2) 18-30 | 1.6 (0.9-2.6) | P12 = .0726 |
| (3) 31-45 | 2.1 (1.4-3.3) | P13 = .0006 |
| (4) Older than 45 | 2.5 (1.6-3.9) | P14 < .0001 |
| Blasts in bone marrow before transplantation5-151 | ||
| (1) Less than 5% | 1.00 | P5-152overall < .0001 |
| (2) 5%-20% | 1.7 (1.3-2.3) | P12 = .0002 |
| (3) More than 20% | 2.5 (1.7-3.6) | P13 < .0001 |
| (4) Unknown | 1.2 (0.8-1.8) | P14 = .3033 |
| Platelets before transplantation | ||
| (1) ≥ 100 × 109/L < 100 × 109/L | 1.00 | P5-152overall = .0025 |
| (2) First 6 mos after transplantation5-153 | 1.8 (1.3-2.7) | P12 = .0010 |
| (3) > 6 mos after transplantation5-153 | 0.9 (0.6-1.5) | P13 = .7834 |
| (4) Unknown | 1.3 (0.8-2.0) | P14 = .2144 |
| Variables . | Relative risk of relapse or death (95% CI) . | P . |
|---|---|---|
| Age, y5-150 | ||
| (1) Younger than 18 | 1.00 | P5-152overall = .0002 |
| (2) 18-30 | 1.6 (0.9-2.6) | P12 = .0726 |
| (3) 31-45 | 2.1 (1.4-3.3) | P13 = .0006 |
| (4) Older than 45 | 2.5 (1.6-3.9) | P14 < .0001 |
| Blasts in bone marrow before transplantation5-151 | ||
| (1) Less than 5% | 1.00 | P5-152overall < .0001 |
| (2) 5%-20% | 1.7 (1.3-2.3) | P12 = .0002 |
| (3) More than 20% | 2.5 (1.7-3.6) | P13 < .0001 |
| (4) Unknown | 1.2 (0.8-1.8) | P14 = .3033 |
| Platelets before transplantation | ||
| (1) ≥ 100 × 109/L < 100 × 109/L | 1.00 | P5-152overall = .0025 |
| (2) First 6 mos after transplantation5-153 | 1.8 (1.3-2.7) | P12 = .0010 |
| (3) > 6 mos after transplantation5-153 | 0.9 (0.6-1.5) | P13 = .7834 |
| (4) Unknown | 1.3 (0.8-2.0) | P14 = .2144 |
P23 = .1016;P24 = .0114;P34 = .2185.
P23 = .0496;P24 = .0725;P34 = .0012.
3 df.
Different relative risks in early and late posttransplantation periods indicate a covariate with nonproportional hazards. Patients with fewer than 100 × 109/L platelets before transplantation have a significantly higher rate of disease-free survival than patients with ≥ 100 × 109/L platelets before transplantation in the first 6 months after transplantation; among patients surviving 6 months or more after transplantation, the pretransplantation platelet count has no prognostic importance.
P12 = probability of testing (1) = (2); P13 = probability of testing (1) = (3); P14 = probability of testing (1) = (4).